Basel Medical Group Ltd (NASDAQ:BMGL) Sees Large Decrease in Short Interest

Posted by Lauren Steadman on Oct 10th, 2026

Basel Medical Group Ltd (NASDAQ:BMGL – Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 11,310 shares, a decline of 92.9% from the September 15th total of 159,585 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily trading volume, of 57,193 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Basel Medical Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has an average rating of “Sell”.

View Our Latest Research Report on BMGL

Basel Medical Group Price Performance

NASDAQ BMGL opened at $3.75 on Friday. Basel Medical Group has a 52 week low of $2.56 and a 52 week high of $21.72. The stock has a fifty day moving average of $4.63 and a 200-day moving average of $6.25.

About Basel Medical Group

(Get Free Report)

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.